These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28893104)

  • 1. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
    Inoue T; Tanihara H
    Expert Opin Pharmacother; 2017 Oct; 18(15):1669-1673. PubMed ID: 28893104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.
    Honjo M; Tanihara H
    Jpn J Ophthalmol; 2018 Mar; 62(2):109-126. PubMed ID: 29445943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ripasudil: first global approval.
    Garnock-Jones KP
    Drugs; 2014 Dec; 74(18):2211-5. PubMed ID: 25414122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells.
    Kaneko Y; Ohta M; Inoue T; Mizuno K; Isobe T; Tanabe S; Tanihara H
    Sci Rep; 2016 Jan; 6():19640. PubMed ID: 26782355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
    Komizo T; Ono T; Yagi A; Miyata K; Aihara M
    Jpn J Ophthalmol; 2019 Jan; 63(1):40-45. PubMed ID: 30368633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction Between Pilocarpine and Ripasudil on Intraocular Pressure, Pupil Diameter, and the Aqueous-Outflow Pathway.
    Yamagishi-Kimura R; Honjo M; Komizo T; Ono T; Yagi A; Lee J; Miyata K; Fujimoto T; Inoue T; Tanihara H; Nishida J; Uchida T; Araki Y; Aihara M
    Invest Ophthalmol Vis Sci; 2018 Apr; 59(5):1844-1854. PubMed ID: 29677344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M;
    Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, efficacy, and patient selection of ripasudil in patients with uncontrolled glaucoma with maximum conventional medical therapy.
    Jethva J; Bhagat P; Prajapati K; Tank G
    Indian J Ophthalmol; 2022 Jun; 70(6):2020-2023. PubMed ID: 35647972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on ripasudil for the treatment of glaucoma and ocular hypertension.
    Testa V; Ferro Desideri L; Della Giustina P; Traverso CE; Iester M
    Drugs Today (Barc); 2020 Sep; 56(9):599-608. PubMed ID: 33025953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits.
    Ohta Y; Takaseki S; Yoshitomi T
    Jpn J Ophthalmol; 2017 Sep; 61(5):423-432. PubMed ID: 28653193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.
    Sato S; Hirooka K; Nitta E; Ukegawa K; Tsujikawa A
    Adv Ther; 2016 Sep; 33(9):1628-34. PubMed ID: 27438467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients.
    Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Sotozono C; Kinoshita S
    J Ocul Pharmacol Ther; 2020 May; 36(4):229-233. PubMed ID: 32175792
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma.
    Kusuhara S; Katsuyama A; Matsumiya W; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):809-814. PubMed ID: 29468405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure.
    Inoue K; Okayama R; Shiokawa M; Ishida K; Tomita G
    Int Ophthalmol; 2018 Feb; 38(1):93-98. PubMed ID: 28063100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rho-associated kinase inhibitors: a novel glaucoma therapy.
    Inoue T; Tanihara H
    Prog Retin Eye Res; 2013 Nov; 37():1-12. PubMed ID: 23770081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study.
    Futakuchi A; Morimoto T; Ikeda Y; Tanihara H; Inoue T;
    Sci Rep; 2020 Jun; 10(1):10308. PubMed ID: 32587304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy.
    Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
    J Glaucoma; 2017 Feb; 26(2):96-100. PubMed ID: 27661993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
    Acta Ophthalmol; 2015 Jun; 93(4):e254-60. PubMed ID: 25487877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.
    Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2009-2015. PubMed ID: 28711991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rho-kinase inhibitors in the management of glaucoma.
    Berrino E; Supuran CT
    Expert Opin Ther Pat; 2019 Oct; 29(10):817-827. PubMed ID: 31573364
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.